TofAJAK (Tofacitinib) 5mg is a medication used to treat moderate to severe active rheumatoid arthritis (RA) in adult patients who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs). It is a Janus kinase (JAK) inhibitor that works by blocking the activity of JAK enzymes, which are involved in the production of pro-inflammatory cytokines.
Composition: Each tablet of TofAJAK contains 5mg of Tofacitinib (an active pharmaceutical ingredient).
Mechanism of Action: TofAJAK works by inhibiting the activity of JAK enzymes, which are involved in the signaling pathways of various pro-inflammatory cytokines. This reduces the production of these cytokines and leads to a decrease in inflammation and joint damage.
Dosage: The recommended dose of TofAJAK is 5mg taken orally twice daily. The dosage may be adjusted based on individual patient response and clinical improvement.
Uses: TofAJAK is used to treat:
- Moderate to severe active rheumatoid arthritis (RA) in adult patients who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs)
- Active psoriatic arthritis (PsA) in adult patients who have had an inadequate response to DMARDs
- Giant cell arteritis (GCA) in adult patients who have had an inadequate response to corticosteroids
Side Effects: Common side effects of TofAJAK include:
- Nasopharyngitis
- Upper respiratory tract infections
- Headache
- Fatigue
- Diarrhea
- Nausea
- Abdominal pain
Rare but serious side effects include:
- Increased risk of infections, including serious infections such as tuberculosis, fungal infections, and bacterial infections
- Increased risk of lymphoma, including non-melanoma skin cancer
- Increased risk of cardiovascular events, including heart attack, stroke, and hypertension
Recommendation: TofAJAK is recommended for patients with moderate to severe active RA or PsA who have had an inadequate response to DMARDs. Patients with a history of hypersensitivity reactions to Tofacitinib or other JAK inhibitors should not receive TofAJAK.
Important Note:
- TofAJAK should be used under the guidance of a healthcare provider with experience in the treatment of rheumatoid arthritis and psoriatic arthritis.
- Patients with a history of tuberculosis, fungal infections, or other serious infections should be closely monitored while taking TofAJAK.
- TofAJAK may interact with other medications, such as immunosuppressants, anticoagulants, and NSAIDs. Patients should inform their healthcare provider of all medications they are taking before starting TofAJAK therapy.
- Patients should be advised to report any symptoms of hypersensitivity reactions, such as rash, itching, swelling, or difficulty breathing.
Reviews
There are no reviews yet.